Solid Biosciences Inc. Stock News
$5.75
4.17%
day before yesterday
Nasdaq,
Nov 01, 09:00 pm CET
Solid Biosciences Inc. Stock News
Neutral
GlobeNewsWire
●
about one month ago
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees.
Neutral
GlobeNewsWire
●
about 2 months ago
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare C...
Neutral
GlobeNewsWire
●
about 2 months ago
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired employees.
Neutral
GlobeNewsWire
●
3 months ago
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 –
Neutral
GlobeNewsWire
●
4 months ago
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
Neutral
GlobeNewsWire
●
5 months ago
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired employees.
Positive
InvestorPlace
●
6 months ago
Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.
Positive
InvestorPlace
●
6 months ago
Solid Biosciences (NASDAQ: SLDB ) just reported results for the first quarter of 2024. Solid Biosciences reported earnings per share of -64 cents.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
